Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RETRACTED: Sudha et al. Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol, a Thyrointegrin α<sub>v</sub>β<sub>3</sub> Antagonist as a Radio- and Chemo-Sensitizer in Pancreatic Cancer. <i>Biomedicines</i> 2022, <i>10</i>, 795.

Biomedicines·2025
Same author

RETRACTED: Godugu et al. Nanoformulated Ajwa (Phoenix Dactylifera) Bioactive Compounds Improve the Safety of Doxorubicin Without Compromising Its Anticancer Efficacy in Breast Cancer. <i>Molecules</i> 2020, <i>25</i>, 2597.

Molecules (Basel, Switzerland)·2025
Same author

RETRACTED: Block et al. Fluorinated Analogs of Organosulfur Compounds from Garlic (<i>Allium sativum</i>): Synthesis, Chemistry and Anti-Angiogenesis and Antithrombotic Studies. <i>Molecules</i> 2017, <i>22</i>, 2081.

Molecules (Basel, Switzerland)·2025
Same author

Editorial Expression of Concern: Nano-Targeted Delivery of Toremifene, an Estrogen Receptor-α Blocker in Prostate Cancer.

Pharmaceutical research·2025
Same author

Correction: Abou-ElNaga et al. Novel Nano-Therapeutic Approach Actively Targets Human Ovarian Cancer Stem Cells after Xenograft into Nude Mice. <i>Int. J. Mol. Sci</i>. 2017, <i>18</i>, 813.

International journal of molecular sciences·2025
Same author

RETRACTED: El-Far et al. Thymoquinone and Curcumin Defeat Aging-Associated Oxidative Alterations Induced by D-Galactose in Rats' Brain and Heart. <i>Int. J. Mol. Sci.</i> 2021, <i>22</i>, 6839.

International journal of molecular sciences·2024

Related Experiment Video

Updated: Jun 11, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Pharmacogenomics in thrombosis.

Shaker A Mousa1

  • 1Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA.

Methods in Molecular Biology (Clifton, N.J.)
|July 10, 2010
PubMed
Summary
This summary is machine-generated.

Genetic variations significantly impact how individuals respond to warfarin, a key medication for preventing blood clots. Pharmacogenomics helps personalize drug therapy for better safety and effectiveness in managing thromboembolic disorders.

More Related Videos

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Related Experiment Videos

Last Updated: Jun 11, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Area of Science:

  • Pharmacogenomics
  • Thrombosis Research
  • Medical Genetics

Background:

  • Genetic abnormalities are critical in thromboembolic complications.
  • Pharmacogenomics aims to personalize medication for improved safety and efficacy.
  • Warfarin dosing is known to be influenced by genetic factors.

Purpose of the Study:

  • To highlight the role of pharmacogenomics in managing thromboembolic disorders.
  • To emphasize the impact of genetic variations on drug response.
  • To underscore the importance of genetic information in optimizing pharmacotherapy.

Main Methods:

  • Review of existing literature on genetic variations and drug response.
  • Analysis of studies focusing on CYP2C9 and VKORC1 gene polymorphisms.
  • Synthesis of pharmacogenomic data related to warfarin therapy.

Main Results:

  • Specific genetic variations, such as in CYP2C9 and VKORC1, significantly affect warfarin dose requirements.
  • Individual genetic makeup influences the benefit-to-risk ratio of warfarin therapy.
  • Pharmacogenomic insights are essential for predicting drug response.

Conclusions:

  • Genetic information is crucial for tailoring warfarin therapy.
  • Personalized pharmacotherapy improves the management of thromboembolic disorders.
  • Pharmacogenomics enhances the safety and efficacy of anticoagulant treatment.